173 related articles for article (PubMed ID: 16888272)
1. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension.
Ariff B; Zambanini A; Vamadeva S; Barratt D; Xu Y; Sever P; Stanton A; Hughes A; Thom S
Stroke; 2006 Sep; 37(9):2381-4. PubMed ID: 16888272
[TBL] [Abstract][Full Text] [Related]
2. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
3. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
[TBL] [Abstract][Full Text] [Related]
5. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Baguet JP; Asmar R; Valensi P; Nisse-Durgeat S; Mallion JM
Vasc Health Risk Manag; 2009; 5(1):175-83. PubMed ID: 19436670
[TBL] [Abstract][Full Text] [Related]
6. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Taniguchi I; Kawai M; Date T; Yoshida S; Seki S; Taniguchi M; Shimizu M; Mochizuki S
Circ J; 2006 Aug; 70(8):995-1000. PubMed ID: 16864931
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study.
Ludwig M; Stapff M; Ribeiro A; Fritschka E; Tholl U; Smith RD; Stumpe KO
Clin Ther; 2002 Jul; 24(7):1175-93. PubMed ID: 12182261
[TBL] [Abstract][Full Text] [Related]
9. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Barrios V; Escobar C; Tomás JP; Calderon A; Echarri R
Clin Ther; 2008 Jan; 30(1):98-107. PubMed ID: 18343246
[TBL] [Abstract][Full Text] [Related]
11. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall structure and haemodynamics: protocol and baseline demographics.
Ariff B; Stanton A; Barratt D; Augst A; Glor F; Poulter N; Sever P; Xu Y; Hughes A; Thom SA
J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):116-22. PubMed ID: 12228852
[TBL] [Abstract][Full Text] [Related]
13. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension.
Ono H; Minatoguchi S; Watanabe K; Yamada Y; Mizukusa T; Kawasaki H; Takahashi H; Uno T; Tsukamoto T; Hiei K; Fujiwara H
Hypertens Res; 2008 Feb; 31(2):271-9. PubMed ID: 18360047
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial.
Schneider MP; Delles C; Klingbeil AU; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):49-56. PubMed ID: 18404609
[TBL] [Abstract][Full Text] [Related]
17. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Malmqvist K; Kahan T; Edner M; Bergfeldt L
Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
19. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
Petrovic I; Petrovic D; Vukovic N; Zivanovic B; Dragicevic J; Vasiljevic Z; Babic R
J Int Med Res; 2005; 33 Suppl 1():39A-49A. PubMed ID: 16222899
[TBL] [Abstract][Full Text] [Related]
20. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
